The Big Idea
Costa Rica | Halting progress
Siobhan Morden | June 4, 2021
This document is intended for institutional investors and is not subject to all of the independence and disclosure standards applicable to debt research reports prepared for retail investors.
Progress on Costa Rica’s public employment legislation has become critical for the country’s pending program with the International Monetary Fund. A final draft of the legislation is done and working its way forward. That might allow the legislation to focus on the next important item on the agenda: approval of the IMF loan itself along with a series of other sizable multilateral loans.
It has been slow and halting process. But the final draft legislation of Costa Rica’s important public employment bill is now scheduled for a first-floor vote between June 14 and June 18. This will represent an important commitment to the IMF program. The program set an end-of-May deadline for real progress on this front ahead of mid-October disbursement of funds. There were discussions on more than 350 motions since early March with a final draft last week. That draft then went for an 8-day review to those public institutions affected by the legislation, and the review concluded June 3. Then comes an important floor vote after two to three days of discussion that next heads to the constitutional committee for 30 days prior to a final second floor vote. The draft legislation already underwent an important test with over two-thirds support for inclusion of the universities and municipalities. This suggests broad bipartisan support for a rigorous reform. The first vote will need to garner two-thirds support to reassure against risks of pushback from the constitutional court after an initial judiciary report of unconstitutionality. The IMF program does not stipulate any specific criteria; however broader coalition support requires a rigorous reform.
The progress on the public employment bill may allow the legislature to shift attention to the next important item on the agenda: the approval of the IMF loan itself. The deadlines are quickly approaching for approval of several multilateral loans including a $300 million CABEI loan, a $300 million World Bank loan (request for extension of June 15 deadlines) and the $1.778 billion 3-year IMF loan (initial disbursement of $583 million). There has been almost no progress on legislative approval of the $2.5 billion in external funding needs for this year waiting for delayed approval of $1.2 billion of loans above and another $1.3 billion in multilateral loans still under development.
Exhibit 1: Status of major loans to Costa Rica
The multilateral issuance at 4.7% of GDP represents an important part of the 13.5% of GDP 2021 gross financing program. It also facilitates easier and cheaper access to domestic funding markets. The investor sentiment remains critical. High debt service cannibalizes the budget, and a high cost of funding undermines medium term solvency ratios. The success of the IMF program has delivered a positive shock on lowering both the cost of funding and the rollover risk of a large funding program with 10-year CRC rates falling from 9.39% on January 5 to 8.12% on May 10 and a duration extension at the May 26 auction to 2036 maturities. The cumulative local debt issuance at CRC1.72 trillion in 1H21 was near the CRC1.8 trillion target that included $600 million in multilateral issuance with depth and breadth in the local markets dependent upon the IMF as an anchor for investor sentiment. The legislature will soon have to show support to the economic reform agenda as well as approve the IMF loan program to reinforce the virtuous circle on the carry returns.
This material is intended only for institutional investors and does not carry all of the independence and disclosure standards of retail debt research reports. In the preparation of this material, the author may have consulted or otherwise discussed the matters referenced herein with one or more of Amherst Pierpont’s trading desks, any of which may have accumulated or otherwise taken a position, long or short, in any of the financial instruments discussed in or related to this material. Further, Amherst Pierpont may act as a market maker or principal dealer, and may have proprietary interests that differ or conflict with the recipient hereof, in connection with any financial instrument discussed in or related to this material.
This message, including any attachments or links contained herein, is subject to important disclaimers, conditions, and disclosures regarding Electronic Communications, which you can find at https://apsec.com/disclaimers.
Copyright ©2022 Amherst Pierpont Securities LLC and its affiliates (“Amherst Pierpont”). All rights reserved. Amherst Pierpont Securities LLC is a member of FINRA and SIPC. This material is intended for limited distribution to institutions only and is not publicly available. Any unauthorized use or disclosure is prohibited.
In making this material available, Amherst Pierpont (i) is not providing any advice to the recipient, including, without limitation, any advice as to investment, legal, accounting, tax and financial matters, (ii) is not acting as an advisor or fiduciary in respect of the recipient, (iii) is not making any predictions or projections and (iv) intends that any recipient to which Amherst Pierpont has provided this material is an “institutional investor” (as defined under applicable law and regulation, including FINRA Rule 4512 and that this material will not be disseminated, in whole or part, to any third party by the recipient.
The author of this material is an economist, desk strategist or trader. In the preparation of this material, the author may have consulted or otherwise discussed the matters referenced herein with one or more of Amherst Pierpont’s trading desks, any of which may have accumulated or otherwise taken a position, long or short, in any of the financial instruments discussed in or related to this material. Further, Amherst Pierpont or any of its affiliates may act as a market maker or principal dealer, and may have proprietary interests that differ or conflict with the recipient hereof, in connection with any financial instrument discussed in or related to this material.
This material (i) has been prepared for information purposes only and does not constitute a solicitation or an offer to buy or sell any securities, related investments or other financial instruments, (ii) is neither research, a “research report” as commonly understood under the securities laws and regulations promulgated thereunder nor the product of a research department, (iii) or parts thereof may have been obtained from various sources, the reliability of which has not been verified and cannot be guaranteed by Amherst Pierpont, (iv) should not be reproduced or disclosed to any other person, without Amherst Pierpont’s prior consent and (v) is not intended for distribution in any jurisdiction in which its distribution would be prohibited.
In connection with this material, Amherst Pierpont (i) makes no representation or warranties as to the appropriateness or reliance for use in any transaction or as to the permissibility or legality of any financial instrument in any jurisdiction, (ii) believes the information in this material to be reliable, has not independently verified such information and makes no representation, express or implied, with regard to the accuracy or completeness of such information, (iii) accepts no responsibility or liability as to any reliance placed, or investment decision made, on the basis of such information by the recipient and (iv) does not undertake, and disclaims any duty to undertake, to update or to revise the information contained in this material.
Unless otherwise stated, the views, opinions, forecasts, valuations, or estimates contained in this material are those solely of the author, as of the date of publication of this material, and are subject to change without notice. The recipient of this material should make an independent evaluation of this information and make such other investigations as the recipient considers necessary (including obtaining independent financial advice), before transacting in any financial market or instrument discussed in or related to this material.